PDE9A and early-onset autosomal dominant Alzheimer disease: Our current findings enhance previous findings that PDE9A inhibitors elevate cGMP62 and enhance synaptic plasticity and cognitive function in rodents.62, 63, 64, 65, 66 PDE9A inhibitors are currently being pursued for the treatment of mild cognitive impairment and early-stage Alzheimer's disease by several pharmaceutical companies.